Australia's Adherium Group announced clearance to sell its SmartTurbo and SmartTouch "smart inhaler" devices in Canada. They improve adherence by tracking usage and sending reminders. The SmartTurbo is used with AstraZeneca's ($AZN) Symbicort Turbuhaler and the SmartTouch works with a variety of metered dose inhalers, including those made by GlaxoSmithKline ($GSK). Adherium Group CEO Garth Sutherland said, "We are committed to ensuring our devices, which are proven to significantly improve the quality of life for people with respiratory diseases, are able to be supplied into all the major markets of the world. This clearance to market allows us to add Canada to the international markets which we already supply, including the US, Europe, China, Australia and New Zealand." Release